CompletedNot Applicable

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

United States20 participantsStarted 2019-06-11

Plain-language summary

Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * LVEF \<50% measured within 6 months of index hospitalization * Clinically identified volume overload with at least one sign of volume overload (pre-admission fluid weight gain, edema, increased DOE, PND, orthopnea, JVD on examination) and a need for intravenous diuretic therapy Exclusion Criteria: * Baseline sCr \>3.0mg/dL and K+ \<3.0 and \>5.5mEq/L * Hemoglobin \< 9.0g/dL * Systemic systolic blood pressure consistently \<100mm Hg * Patients being treated with hemodialysis, CKD stage 5 or s/p renal transplantation * S/P cardiac transplant or LVAD implantation/total artificial heart * Pregnancy or of child bearing potential * Allergy to iodine * Unable to provide informed consent to participate in the study

What they're measuring

Assessment of ProEnkephalin to detect acute kidney injury in hospitalized to identify baseline values of PENK biomarkers of AKI in relation to measured intravascular volume.

Timeframe: Hospital admission through hospital discharge, approximately 6 days

Trial details

NCT IDNCT04019314

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-06

View on ClinicalTrials.gov More Heart Failure trials